There are three main biological groups: HR-positive/HER2-negative (HR+/HER2-, ~70%), HER2-positive (HER2+, ~15–20%) and triple-negative breast cancer (TNBC, HR-/HER2-, ~15%) [6,7]. Here, ERBB2 is linked to triple-negative breast carcinoma.